In February, the German Atrial Fibrillation Network (AFNET) enrolled the first patients in the AXAFA – AFNET 5 trial. The trial is designed to test whether novel oral anticoagulants (NOACs) are also suitable for stroke prevention in atrial fibrillation patients undergoing catheter ablation.
This and three other trials as well as the AFNET infrastructure are being partially funded by the German Centre for Cardiovascular Research (DZHK) since January 2015.
AFNET press release on the trial:
AXAFA trial examines the NOAC Apixaban during AF catheter ablation